Trending menu:
Comment
-
1 May 2019
Top ten drugs in biosimilar trials globally
The number one drug in biosimilar clinical trials by count is adalimumab biosimilar, referencing the branded biologic Humira.
-
10 April 2019
Governments are playing a bigger role in cell and gene therapy manufacturing
Currently, the UK accounts for 16% of global cell therapy manufacturing facilities, according to GlobalData’s Contract Service Provider Database.
-
3 April 2019
What are the top biomarkers in oncology clinical trials?
Biomarkers used in clinical studies may verify the mechanism of action of a drug, guide subject and dose selection and minimise patient safety risks.
-
15 March 2019
ViiV Healthcare unveils Phase III trial results of monthly shots to combat HIV
The results investigated the efficacy and safety of cabotegravir/rilpivirine, the company’s once-monthly injection for treating HIV.
-
11 February 2019
How to Source Non-IMP Supplies for Clinical Trials
Tim Holmes, Manager, Clinical Oversight of Supplies, Biogen, offers considerations on how to obtain non-IMP supplies for clinical trials
-
30 January 2019
Industry Viewpoints: Patient Recruitment and Expanded Access
In the latest Industry Viewpoint, Howard Fingert speaks to CTA’s Elizabeth Williams about the challenges of patient recruitment
-
28 January 2019
Medical Device Development – Challenges of an SME
John Shillingford, Clinical Operations Director, Orsus Medical, describes the inherent challenges facing small- to mid-sized medical device companies
-
18 January 2019
Managing Blinding Requirements in IRT: An Overview
Francesco Spoto, Clinical Project Manager, explores the opportunities of using IRT solutions to manage blinded information in clinical trials
-
16 January 2019
Industry Viewpoints: Clinical Trials in Asia – Key Considerations
Mainfong Ang, Amgen, sits down with CTA’s Jisong Seo about the difficulties of clinical operations in Asia
-
14 January 2019
Integrating New Assets: A Supply Chain Perspective
Barrett Glasser, Associate Director, Clinical Drug Supply, Biogen, provides an overview on how to on board newly acquired therapeutic assets